TickerFacts.

LB Pharmaceuticals Inc (LBRX): Cash & Equivalents

Annual figures by period end, from SEC filings.

$250.17M
As of 2025-12-31
$283.11M
As of 2026-06-30
2024-12-31: $22.98M2025-12-31: $250.17M$250.17M
2024-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$250.17M+988.8%2026-03-26, Balance as of period end
2024-12-31$22.98Mn/a2026-03-26, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
LB Pharmaceuticals Inc (LBRX)2025-12-31$250.17M+988.8%
Atea Pharmaceuticals, Inc. (AVIR)2025-12-31$95.71M+47.9%
ADC Therapeutics SA (ADCT)2025-12-31$261.34M+4.2%
Omeros Corp (OMER)2025-12-31$9.66M+184.1%
Sionna Therapeutics, Inc. (SION)2025-12-31$58.45M+54.7%
Prothena Corp Public Ltd Co (PRTA)2025-12-31$307.53M-34.8%
ARS Pharmaceuticals, Inc. (SPRY)2025-12-31$41.32M-18.7%
Liquidia Corp (LQDA)2025-12-31$190.68M+8.0%
Cartesian Therapeutics, Inc. (RNAC)2025-12-31$125.14M-41.1%

Compare LBRX, AVIR, ADCT, OMER side by side · Screen every company in Pharmaceutical Preparations ↗